Compare Rocket Companies Inc. Class A Common Stock (RKT) vs Teladoc Health Inc (TDOC) Price & Performance

Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.

Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.

Teladoc Health trades at $6.00, showing modest daily gains but remains near multi-year lows with bearish technical signals. The company maintains strong revenue around $2.5B annually but continues posting net losses, though improving from historical levels. Recent management changes and ongoing BetterHelp challenges create uncertainty, while the Integrated Care segment shows promise. Valuation metrics appear attractive with P/S of 0.43 and P/B of 0.83, suggesting potential undervaluation if profitability improves.

The stock presents a high-risk opportunity with significant upside potential if management can stabilize operations and achieve profitability. Analyst consensus targets $8.83 (47% upside) with no sell ratings, but execution risks remain elevated. Key catalysts include successful CFO transition, BetterHelp stabilization, and Integrated Care margin expansion. Investors should weigh the attractive valuation against persistent losses and competitive pressures in telehealth.